Dengue Vaccine Composition Serotype Segmentation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack an effective vaccine for dengue disease, which is a significant public health concern due to its high incidence and mortality rates, particularly in tropical regions, with no licensed vaccine available to prevent the disease effectively.

Innovation Solution

A vaccine composition comprising a dengue antigen such as a live attenuated or inactivated dengue virus, a chimeric dengue virus, or dengue virus-like particles, or a nucleic acid construct that expresses dengue antigens, administered to induce neutralizing antibodies and provide protection against dengue disease.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If no vaccine is available, then dengue disease prevention relies on mosquito control and symptomatic treatment, but this results in high incidence and mortality rates with limited efficacy

Engineering Contradiction:

Improvedisease prevention efficacyVSAvoidpublic health outcome

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The vaccine composition is segmented into multiple serotype-specific components (DEN-1, DEN-2, DEN-3, DEN-4) to provide targeted protection against each dengue virus serotype, thereby improving overall prevention efficacy across different viral strains

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces a vaccine composition as an intermediary preventive measure that stimulates the immune system to produce neutralizing antibodies, serving as a bridge between mosquito exposure and disease prevention, thereby reducing reliance on mosquito control alone

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If mosquito control measures are used, then some prevention is achieved, but these measures are limited in efficacy and difficult to enforce

Engineering Contradiction:

Improveprevention implementationVSAvoidprevention efficacy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

Instead of controlling the vector (mosquito) to prevent disease, the patent inverts the approach by directly protecting the host through vaccination, shifting the prevention strategy from environmental control to individual immunity building

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The vaccine enables the immune system to self-protect by producing its own neutralizing antibodies against dengue virus, making the prevention mechanism self-sustaining and independent of external mosquito control enforcement

Inventive Principle:

Principle #25Self-service

3Ease of manufacture

If symptomatic treatment is provided, then patient care is available, but this does not prevent high mortality rates from dengue hemorrhagic fever

Engineering Contradiction:

Improvetreatment availabilityVSAvoidmortality reduction

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The vaccine provides preliminary protective action by pre-stimulating the immune system to produce neutralizing antibodies before dengue virus exposure occurs, preventing the development of severe disease rather than treating symptoms after infection

Inventive Principle:

Principle #10Preliminary action

4Reliability

If live attenuated or inactivated dengue virus is used as antigen, then immune response is elicited, but vaccine safety and efficacy must be balanced

Engineering Contradiction:

Improveimmune response inductionVSAvoidvaccine safety

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs different viral states (live attenuated vs. inactivated) with modified parameters such as viral viability and antigenicity to balance immune response induction with safety, allowing selection based on specific deployment requirements

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The vaccine composition may combine multiple antigen types (live attenuated, inactivated, chimeric, VLPs) in a composite formulation to leverage the advantages of each component while mitigating their individual limitations regarding safety and efficacy

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The vaccine composition significantly reduces the incidence and severity of dengue disease, including severe forms like dengue hemorrhagic fever, by eliciting a robust immune response and providing protection against multiple serotypes of the dengue virus.

Implementation Method 1

a nucleic acid construct or viral vector which is able to express in a human cell a dengue antigen which is a dengue VLP

Methodology Applied

Scientific EffectGene expression:

Data Source

PatentEP3932422A1Vaccine compositions for the prevention of dengue virus infection

Publication Date: 2022.01.05 SANOFI PASTEUR SA

Figure 1

AI summary

The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.